Remarkably, in the current study, unlike Devillier et al.’s, patients with NPM1 and biallelic CEBPA mutation, in the absence of cytogenetic abnormalities of AML‐MRC are excluded from the group, following the latest WHO update. Here, CEBPA is linked to acute myeloid leukemia.